FOXO4-DRI Research

FOXO4-DRI represents a promising therapeutic strategy for targeting senescent cells across various diseases, including cancer, pulmonary fibrosis, and age-related conditions. By selectively inducing apoptosis in senescent cells, FOXO4-DRI can restore tissue homeostasis and improve treatment outcomes. Further research is needed to fully understand its potential and optimize its application in clinical settings.

Applications in Cancer Treatment

FOXO4-DRI has been studied for its potential to enhance the radiosensitivity of non-small cell lung cancer (NSCLC) cells. By inducing apoptosis in senescent cancer-associated fibroblasts, FOXO4-DRI can reduce radioresistance in NSCLC, making cancer cells more susceptible to radiotherapy. This approach not only targets the tumor cells but also addresses the tumor microenvironment, which plays a crucial role in cancer progression and treatment resistance.¹

Role in Pulmonary Fibrosis

In models of pulmonary fibrosis, FOXO4-DRI has been shown to decrease the number of senescent cells and reduce the expression of senescence-associated secretory phenotype (SASP) factors. This results in the attenuation of fibrosis-related morphological changes and collagen deposition, suggesting that FOXO4-DRI could serve as a viable therapeutic option for treating pulmonary fibrosis.²

Impact on Age-Related Conditions

FOXO4-DRI has demonstrated potential in alleviating age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. By promoting the apoptosis of these senescent cells, FOXO4-DRI improves the testicular microenvironment and restores testosterone levels, highlighting its potential in treating male late-onset hypogonadism.³

Effects on Cartilage Regeneration

In the context of cartilage regeneration, FOXO4-DRI has been used to selectively remove senescent cells from in vitro expanded human chondrocytes. While it effectively reduces the senescence level in these cells, its impact on enhancing chondrogenic potential and cartilage formation requires further investigation.⁴

References

1. Zhao, Y., Zhang, J., & Han, X. (2019). FOXO4 D-retro-inverso peptide increases radiosensitivity of non-small cell lung cancer cells. Chinese journal of radiological medicine and protection, 39, 881-886. https://doi.org/10.3760/CMA.J.ISSN.0254-5098.2019.12.001.
2. Han, X., Yuan, T., Zhang, J., Shi, Y., Li, D., Dong, Y., & Fan, S. (2022). FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway. Journal of Cellular and Molecular Medicine, 26, 3269 – 3280. https://doi.org/10.1111/jcmm.17333.
3. Zhang, C., Xie, Y., Chen, H., Lv, L., Yao, J., Zhang, M., Xia, K., Feng, X., Li, Y., Liang, X., Sun, X., Deng, C., & Liu, G. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY), 12, 1272 – 1284. https://doi.org/10.18632/aging.102682.
4. Huang, Y., He, Y., Makarcyzk, M., & Lin, H. (2021). Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Frontiers in Bioengineering and Biotechnology, 9. https://doi.org/10.3389/fbioe.2021.677576.